Gross Margin: ~89% - 92%
Sales Growth (Q/Q): ~40% - 60%
P/E (Current),~6.1 - 6.3,"Extremely low. The market is still cautious, which offers potential for a ""value"" investment."
Forward P/E,~10.8,"Slightly up from current, reflecting expected R&D investments in 2026."
Free Cash Flow,~$77M (for 2025),"The company has generated significant cash, ending 2025 with $154.6M in cash."
ROE,>200%,"The number is skewed upwards due to the recent move to profitability, but shows tremendous efficiency."
Debt/Equity,~0.3 - 0.5,"Low debt, which is excellent for the sector."
Revenue Growth,~25% - 60%,2026 forecast is for revenue between $275M and $290M.
PEG Ratio,n/a,Most platforms do not calculate this due to recent earnings volatility.
Dividend Yield,0%,Typical for biotech; reinvest everything in new developments (e.g. R289).
Analyst Rating,Strong Buy,Average analyst target is around $51.20 (potential for +35%).
Sales Growth (Q/Q): ~40% - 60%
P/E (Current),~6.1 - 6.3,"Extremely low. The market is still cautious, which offers potential for a ""value"" investment."
Forward P/E,~10.8,"Slightly up from current, reflecting expected R&D investments in 2026."
Free Cash Flow,~$77M (for 2025),"The company has generated significant cash, ending 2025 with $154.6M in cash."
ROE,>200%,"The number is skewed upwards due to the recent move to profitability, but shows tremendous efficiency."
Debt/Equity,~0.3 - 0.5,"Low debt, which is excellent for the sector."
Revenue Growth,~25% - 60%,2026 forecast is for revenue between $275M and $290M.
PEG Ratio,n/a,Most platforms do not calculate this due to recent earnings volatility.
Dividend Yield,0%,Typical for biotech; reinvest everything in new developments (e.g. R289).
Analyst Rating,Strong Buy,Average analyst target is around $51.20 (potential for +35%).
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.
Aviso legal
As informações e publicações não se destinam a ser, e não constituem, conselhos ou recomendações financeiras, de investimento, comerciais ou de outro tipo fornecidos ou endossados pela TradingView. Leia mais nos Termos de Uso.